INDV vs JAZZ
INDV: Indivior is a specialty pharmaceutical company dedicated to developing and marketing treatments for substance use disorders and mental health conditions, anchored by its flagship injectable product, SUBLOCADE. JAZZ: A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of innovative treatments.
Side-by-side fundamentals
| Metric | INDV | JAZZ | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $40.45 | $250.41 | |
| Market cap as of 2026-07-23 | $4.9B | $16.0B | |
| P/E as of 2026-07-23 | 19.65 | 543.13 | INDV lower |
| PEG as of 2026-07-23 | 0.83 | 58.02 | INDV lower |
| Net margin as of 2026-07-23 | +19.4% | +0.7% | INDV higher |
| Gross margin as of 2026-07-23 | +81.3% | +88.0% | JAZZ higher |
| Operating margin as of 2026-07-23 | +24.4% | -0.8% | INDV higher |
| ROE as of 2026-07-23 | +159.1% | +0.7% | INDV higher |
| ROA as of 2026-07-23 | +19.1% | +0.3% | INDV higher |
| Debt / equity as of 2026-07-23 | 27.90 | 1.18 | JAZZ lower |
| Revenue growth (YoY) as of 2026-07-23 | +10.3% | +9.2% | INDV higher |
| Revenue CAGR (3y) SEC XBRL | +11.2% | +5.3% | INDV higher |
| Beta as of 2026-07-23 | 0.53 | 0.37 | |
| 1-year return as of 2026-07-22 close | +150.0% | +125.7% | INDV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.